Eye Journal
Reply to ‘Can photoreceptor loss also account for changes in pupil size following panretinal photocoagulation?’ – (Eye 31, 161 (January 2017))
Reply to ‘Can photoreceptor loss also account for changes in pupil size following panretinal photocoagulation?’ Eye 31, 161 (January 2017). doi:10.1038/eye.2016.211 Authors: I Yilmaz & A Ozkaya
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy – (Eye 31, 162 (January 2017))
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy Eye 31, 162 (January 2017). doi:10.1038/eye.2016.214 Authors: D Călugăru & M Călugăru
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy – (Eye 31, 163 (January 2017))
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy Eye 31, 163 (January 2017). doi:10.1038/eye.2016.215 Authors: F Ricci, M Parravano, F Regine, M Sciamanna, M Tedeschi, F Missiroli & M Varano
Recent subspecialty trends in ophthalmology consultant appointments – (Eye 31, 164 (January 2017))
Recent subspecialty trends in ophthalmology consultant appointments Eye 31, 164 (January 2017). doi:10.1038/eye.2016.176 Authors: O Bowes, W Dean & A D Borman
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study – (Eye 31, 166 (January 2017))
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study Eye 31, 166 (January 2017). doi:10.1038/eye.2016.276 Authors: F G Holz, R Tadayoni, S Beatty, A R Berger, M G Cereda, P Hykin, G Staurenghi, K Wittrup-Jensen, J Nilsson, K Kim & S Sivaprasad